Form 4: Fulcrum Therapeutics Director Alan Ezekowitz Granted 36,000 Stock Options

Fulcrum Therapeutics, Inc. Director Alan Ezekowitz was granted 36,000 stock options with an exercise price of $7.38, vesting over one year.

Summary

• Alan Ezekowitz, a Director of Fulcrum Therapeutics, Inc. (FULC), was granted 36,000 stock options.
• The stock options have an exercise price of $7.38 per share.
• The grant date for these options was June 26, 2025.
• The options are scheduled to vest fully on the first anniversary of the grant date (June 26, 2026) or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on continued service.
• The options expire on June 25, 2035.
• Following this transaction, Alan Ezekowitz beneficially owns 36,000 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard practice that aligns the director's financial interests with the long-term performance of the company, indicating continued commitment.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration period, providing a substantial window for potential value realization if the company's stock price appreciates.

Negatives

• The grant itself does not provide immediate cash inflow to the company.
• There is a potential for future dilution of existing shares if and when these options are exercised.

Risks

• The value of the stock options is entirely dependent on Fulcrum Therapeutics' common stock price exceeding the exercise price of $7.38 per share.
• Vesting of the options is subject to Alan Ezekowitz's continued service to the company, meaning the options could be forfeited if service ceases before vesting.
• Future exercise of these options could lead to dilution for current shareholders.

Future Outlook

The vesting schedule for the granted options indicates a future commitment from the director, aligning their incentives with the company's long-term performance and potential stock price appreciation.

Industry Context

Equity grants, such as stock options, are a common and standard form of executive and director compensation in the biotechnology and pharmaceutical industries. This practice aims to incentivize long-term value creation, retain key talent, and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The document is a standard Form 4 filing for an insider transaction and does not contain specific data points for direct comparison to other companies' projects or results. The grant of stock options to a director is a common compensation practice across the industry.

Related Party Transactions

• Grant of 36,000 stock options to Alan Ezekowitz, a Director of Fulcrum Therapeutics, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from incentivized director performance and alignment of interests.
• Management: Alan Ezekowitz's compensation structure is enhanced, further aligning his financial interests with the company's long-term success.

Next Steps

• Continued service by Alan Ezekowitz to ensure the full vesting of the options.
• Potential future exercise of the options by Alan Ezekowitz if Fulcrum Therapeutics' stock price exceeds the exercise price of $7.38.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transactions, Biotechnology, Pharmaceuticals